Monogram Technologies Inc. has released its financial results for the first quarter ended March 31, 2025. The company reported a net loss of $3.2 million, which is an improvement compared to a net loss of $3.5 million in the same quarter of the previous year. Cash and cash equivalents stood at $13.3 million as of March 31, 2025, down from $15.7 million as of December 31, 2024. Marketing and advertising expenses significantly decreased by 63% to $44,000 from $120,000 in the prior-year quarter, primarily due to a shift from external marketing efforts to internal payroll-related expenses. General and administrative expenses were slightly lower at $1.0 million compared to $1.1 million in the prior-year quarter. Research and development expenses saw a slight decrease of 6% to $2.3 million from $2.4 million, primarily due to the completion of the verification and validation phase of the Monogram mBôs™ TKA System robotic system. A significant operational highlight for the quarter was the receipt of FDA 510(k) clearance for the Monogram mBôs™ TKA System, alongside an announcement of a groundbreaking trial to conduct one of the world's first autonomous saw-based robotic TKA surgeries on live patients. The company is focusing on refining the mBôs system, advancing regulatory submissions for expanded clinical applications, and evaluating strategic opportunities for domestic and international growth.